CTXR

Company Overview — What Does Citius Pharmaceuticals, Inc. Do?

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Citius Pharmaceuticals, Inc. (CTXR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Leonard L. Mazur and employs approximately 20 people. With a market capitalization of $19M, CTXR is one of the notable companies in the Healthcare sector.

Citius Pharmaceuticals, Inc. (CTXR) Stock Rating — Avoid (April 2026)

As of April 2026, Citius Pharmaceuticals, Inc. receives a Avoid rating with a composite score of 22.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CTXR ranks #3,988 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Citius Pharmaceuticals, Inc. ranks #689 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CTXR Stock Price and 52-Week Range

Citius Pharmaceuticals, Inc. (CTXR) currently trades at $0.82. The stock lost $0.02 (2.4%) in the most recent trading session. The 52-week high for CTXR is $2.48, which means the stock is currently trading -66.8% from its annual peak. The 52-week low is $0.63, putting the stock 30.7% above its annual trough. Recent trading volume was 290K shares, suggesting relatively thin trading activity.

Is CTXR Overvalued or Undervalued? — Valuation Analysis

Citius Pharmaceuticals, Inc. (CTXR) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.19x, versus the sector average of 2.75x. The price-to-sales ratio is 4.48x, compared to 1.66x for the average Healthcare stock.

At current multiples, Citius Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Citius Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Citius Pharmaceuticals, Inc. (CTXR) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -43.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -29.0% versus the sector average of -33.1%.

On a margin basis, Citius Pharmaceuticals, Inc. reports gross margins of 80.0%, compared to 71.5% for the sector. The operating margin is -228.7% (sector: -66.1%). Net profit margin stands at -238.2%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CTXR Debt, Balance Sheet, and Financial Health

Citius Pharmaceuticals, Inc. has a debt-to-equity ratio of 50.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.99x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $2M. Cash and equivalents stand at $4M.

CTXR has a beta of 1.61, meaning it is more volatile than the broader market — a $10,000 investment in CTXR would be expected to move 60.9% more than the S&P 500 on any given day. The stability factor score for Citius Pharmaceuticals, Inc. is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Citius Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Citius Pharmaceuticals, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-41M. Gross margin was 80.0%. Operating income came in at $-40M.

In Q1 2026, Citius Pharmaceuticals, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-9M. Gross margin was 80.0%. Operating income came in at $-9M.

In FY 2025, Citius Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.38. Net income for the quarter was $-40M. Operating income came in at $-39M.

In Q3 2025, Citius Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.80. Net income for the quarter was $-9M. Operating income came in at $-9M.

Over the past 8 quarters, Citius Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $4M. Investors analyzing CTXR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CTXR Dividend Yield and Income Analysis

Citius Pharmaceuticals, Inc. (CTXR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CTXR Momentum and Technical Analysis Profile

Citius Pharmaceuticals, Inc. (CTXR) has a momentum factor score of 20/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 46/100 reflects moderate short selling activity.

CTXR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Citius Pharmaceuticals, Inc. (CTXR) ranks #689 out of 838 stocks based on the Blank Capital composite score. This places CTXR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CTXR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CTXR vs S&P 500 (SPY) comparison to assess how Citius Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

CTXR Next Earnings Date

No upcoming earnings date has been announced for Citius Pharmaceuticals, Inc. (CTXR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CTXR? — Investment Thesis Summary

The quantitative profile for Citius Pharmaceuticals, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. Momentum is weak at 20/100, a headwind for near-term performance. High volatility (stability score 14/100) increases portfolio risk.

In summary, Citius Pharmaceuticals, Inc. (CTXR) earns a Avoid rating with a composite score of 22.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CTXR stock.

Related Resources for CTXR Investors

Explore more research and tools: CTXR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CTXR head-to-head with peers: CTXR vs AZN, CTXR vs SLGL, CTXR vs VMD.